|
Status |
Public on Nov 05, 2015 |
Title |
Untreated_replicate3 |
Sample type |
RNA |
|
|
Source name |
MDA-MB-231
|
Organism |
Homo sapiens |
Characteristics |
cell line: MDA-MB-231 cell type: triple negative breast adenocarcinoma agent: control
|
Treatment protocol |
For conducting experiments, cells were grown to 80% confluency and serum starved overnight prior to treatment with 500uM DETA/NO for 24 hours.
|
Growth protocol |
MDA-MB-231 human triple negative breast cancer cells were obtained from American Type Culture Collection (ATCC) and cultured in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin in a controlled environment (37°C and 5% CO2).
|
Extracted molecule |
total RNA |
Extraction protocol |
RNA was extracted using the miRNeasy kit (Qiagen) as per manufacturer's protocols.
|
Label |
Biotin
|
Label protocol |
Samples were labeled using the Affymetrix FlashTag™ Biotin HSR RNA Labeling Kit as per manufacturer's protocols.
|
|
|
Hybridization protocol |
The GeneChip® Hybridization, Wash, and Stain Kit was used as per manufacturer’s protocols. The GeneChip® Fluidics Station 450 was used for washing and staining with fluidics script FS450_0002.
|
Scan protocol |
Microarray chips were read on the GeneChip® Scanner 3000 7G with AGCC version 4.0.0.1567.
|
Description |
Sample name: miRNA_C4
|
Data processing |
RMA in Partek
|
|
|
Submission date |
Feb 26, 2015 |
Last update date |
Nov 06, 2015 |
Contact name |
Douglas David Thomas |
E-mail(s) |
ddthomas@uic.edu
|
Phone |
312-996-6156
|
Organization name |
University of Illinois at Chicago
|
Department |
Medicinal Chemistry & Pharmacognosy
|
Street address |
900 S Ashland Ave Room 3306
|
City |
Chicago |
State/province |
IL |
ZIP/Postal code |
60607 |
Country |
USA |
|
|
Platform ID |
GPL19117 |
Series (2) |
GSE66323 |
Nitric oxide regulates gene expression in cancers by controlling histone posttranslational modifications [miRNA-4_0] |
GSE66324 |
Nitric oxide regulates gene expression in cancers by controlling histone posttranslational modifications |
|